Flushed with recent clinical trial wins, Apellis has moved quickly ahead with an initial public offering.
Shanghai-based biotech EOC Pharma has raised $32 million from Chinese investors to help it bring a series of cancer drugs to market.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.
Aimmune chief Stephen Dilly, M.B.B.S., Ph.D., is calling it a day.
A tax credit that allows biopharma companies to recoup some of the cost of developing drugs for rare diseases could be abolished if a Republican tax reform…
Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.
Five Prime Therapeutics has tapped into its existing management to replace current president and CEO Rusty Williams.
Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.
Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.
Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.